Ignite Creation Date:
2024-05-06 @ 1:42 PM
Last Modification Date:
2024-10-26 @ 1:18 PM
Study NCT ID:
NCT04095390
Status:
UNKNOWN
Last Update Posted:
2019-09-19
First Post:
2019-09-16
Brief Title:
A Phase Ⅱ Trial of Pyrotinib Combination With CDK46 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer
Sponsor:
Jinming Yu
Organization:
Shandong Cancer Hospital and Institute
Study Overview
Official Title:
A Phase Ⅱ Trial Program Exploring The Integration Of Novel HER2-targeted Tyrosine Kinase Inhibitor Pyrotinib and CDK46 Inhibitor SHR6390 Into Current ChemotherapyEndocrine Therapy Regimes For Prior Trastuzumab-treated Advanced HER2-positive Breast Cancer
Status:
UNKNOWN
Status Verified Date:
2019-09
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
INPHASE
Brief Summary:
The study is being conducted to evaluate the efficacy safety and tolerability of pyrotinib combination with CDK46 Inhibitor SHR6390 in advanced HER2-Positive breast cancer patients who prior trastuzumab-treated
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None